Avience Biomedicals (NSE:AVIENCE) Stock Based Compensation: ₹0.0 Mil (TTM As of Jan. 2026)


NSE:AVIENCE Avience Biomedicals Ltd NSE:AVIENCE
5 GF Score
Price ₹414.95
View Full Analysis

What is Avience Biomedicals Stock Based Compensation?

Avience Biomedicals NSE:AVIENCE 5 Stock Based Compensation is ₹0.0 Mil as of Jan. 2026. GuruFocus rates NSE:AVIENCE with a GF Score™ of 5/100.

Avience Biomedicals's Stock Based Compensation for the three months ended in Jan. 2026 was ₹0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jan. 2026 was ₹0.0 Mil.

Avience Biomedicals Stock Based Compensation Related Terms

Avience Biomedicals Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Avience Biomedicals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avience Biomedicals Stock Based Compensation Chart

Avience Biomedicals Annual Data
Trend Mar23 Mar24 Mar25
Stock Based Compensation
0.00 0.00 0.00

Avience Biomedicals Quarterly Data
Mar23 Mar24 Mar25 Jan26
Stock Based Compensation 0.00 0.00 0.00 0.00
NSE:AVIENCE
5GF Score
Avience Biomedicals Ltd NSE:AVIENCE
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avience Biomedicals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

What does a Stock Based Compensation of ₹0.0 Mil mean?
Avience Biomedicals (NSE:AVIENCE) has a Stock Based Compensation of ₹0.0 Mil as of Jan. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Avience Biomedicals and its competitors.
Is Avience Biomedicals' Stock Based Compensation too high?
Avience Biomedicals' current Stock Based Compensation is ₹0.0 Mil. Overall, Avience Biomedicals has a GF Score™ of 5/100, reflecting its overall financial health beyond just this single metric.
How does Avience Biomedicals' Stock Based Compensation compare to ABT and SYK?
Avience Biomedicals' Stock Based Compensation of ₹0.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Avience Biomedicals and its competitors. Avience Biomedicals's current Stock Based Compensation is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avience Biomedicals stock overvalued right now?
Avience Biomedicals (NSE:AVIENCE) has a current Stock Based Compensation of ₹0.0 Mil. The current Stock Based Compensation is ₹0.0 Mil. Avience Biomedicals' overall GF Score™ is 5/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Avience Biomedicals (NSE:AVIENCE), the current Stock Based Compensation is ₹0.0 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avience Biomedicals Business Description

Address C-11, Block-C, Community Centre, Unit No-2, 1st Floor, Janakpuri A-3, New Delhi, IND, 110058
Avience Biomedicals Ltd is a medical consumables company focused on the manufacturing of Vitro-Diagnostic (IVD) products and medical devices. Its product offerings include diagnostic solutions used for the detection of diseases, conditions, and infections across laboratory, healthcare, and home-use applications. The company operates in areas including molecular biotechnology, genomics, and diagnostic products, and also provides distribution services for medical technology products in India. Its revenue is generated from Manufactured Goods and Traded Goods and Services, which include the sale of Medical Devices and Consumables.
5GF Score

Get the complete analysis for NSE:AVIENCE

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹414.95
Price